This article was downloaded by: [University of Bath] On: 09 October 2014, At: 14:04 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: <u>http://www.tandfonline.com/loi/lncn20</u>

# KINETIC MODEL OF OXIDATION CATALYZED BY XANTHINE OXIDASE—THE FINAL ENZYME IN DEGRADATION OF PURINE NUCLEOSIDES AND NUCLEOTIDES

Kinga Banach<sup>a</sup>, Elżbieta Bojarska<sup>a</sup>, Zygmunt Kazimierczuk<sup>b c</sup>, Lucyna Magnowska<sup>a</sup> & Agnieszka Bzowska<sup>a</sup>

 $^{\rm a}$  Department of Biophysics , Institute of Experimental Physics, University of Warsaw , Warsaw, Poland

<sup>b</sup> Institute of Chemistry, Agricultural University, Warsaw, Poland

<sup>c</sup> Laboratory of Experimental Pharmacology, Polish Academy of Sciences Medical Research Center, Warsaw, Poland Published online: 15 Nov 2011.

To cite this article: Kinga Banach, Elżbieta Bojarska, Zygmunt Kazimierczuk, Lucyna Magnowska & Agnieszka Bzowska (2005) KINETIC MODEL OF OXIDATION CATALYZED BY XANTHINE OXIDASE—THE FINAL ENZYME IN DEGRADATION OF PURINE NUCLEOSIDES AND NUCLEOTIDES, Nucleosides, Nucleotides and Nucleic Acids, 24:5-7, 465-469, DOI: <u>10.1081/NCN-200060006</u>

To link to this article: <u>http://dx.doi.org/10.1081/NCN-200060006</u>

## PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <a href="http://www.tandfonline.com/page/terms-and-conditions">http://www.tandfonline.com/page/terms-and-conditions</a>



### KINETIC MODEL OF OXIDATION CATALYZED BY XANTHINE OXIDASE—THE FINAL ENZYME IN DEGRADATION OF PURINE NUCLEOSIDES AND NUCLEOTIDES

Kinga Banach and Elżbieta Bojarska Department of Biophysics, Institute of Experimental Physics, University of Warsaw, Warsaw, Poland

**Zygmunt Kazimierczuk** Institute of Chemistry, Agricultural University, Warsaw, Poland and Laboratory of Experimental Pharmacology, Polish Academy of Sciences Medical Research Center, Warsaw, Poland

Lucyna Magnowska and Agnieszka Bzowska Department of Biophysics, Institute of Experimental Physics, University of Warsaw, Warsaw, Poland

• A new kinetic model is presented for analysis of experimental data of oxidation process catalyzed by milk xanthine oxidase. The kinetics for two substrates, xanthine and its analog 2-chloroadenine, in a broad pH range (5.8–9.0) are best described by an equation which is a rational function of degree 2:3 and 2:2, respectively.

**Keywords** Xanthine Oxidase, Enzyme Kinetics, Purine Degradation, Biological Oxidation, Non-Michaelis–Menten Kinetics

#### INTRODUCTION

Xanthine oxidase (XO) is a molybdeno-flavoprotein complex involved in the final stage of degradation of nucleic acids' components. It catalyzes the oxidation of hypoxanthine (Hx) to xanthine (Xan) and subsequently to uric acid that is the end product of purine catabolism in man.<sup>[1]</sup> Accumulation of uric acid in human blood plasma (hyperuricemia) leads to formation and deposition of sodium urate microcrystals in joints, which results in gout.<sup>[2]</sup> Allopurinol, an analog of Hx and a weak XO inhibitor developed 30 years ago, is the only clinically used drug for the treatment of hyperuricemia associated with chronic gout.<sup>[3]</sup>

Supported by the Foundation for Development Diagnostic and Therapy (Warsaw, Poland) and by BST 833/ BF project from University of Warsaw.

Address correspondence to Agnieszka Bzowska, Department of Biophysics, Institute of Experimental Physics, University of Warsaw, 93 Zwirki & Wigury, Warsaw 02-089, Poland; E-mail: abzowska@biogeo.uw.edu.pl

#### K. Banach et al.

XO seems to play an important role that is not limited to oxidation pathway in purine metabolism. It was suggested that the enzyme is involved in pathogenesis of post-ischemic reperfusion tissue injury and in protection against bacterial infection, toxic plants and metabolic xenobiotics by producing reactive oxygen species during the redox cycle.<sup>[4,5]</sup> Serum XO is significantly elevated in various pathological states like hepatitis, inflammation, malignancies and ageing, and it is commonly accepted that reactive oxygen species generated by the enzyme are involved in oxidative damage. Thus, the inhibition of this enzymatic pathway could be beneficial in a broad spectrum of pathologies, and not only in treatment of gout.<sup>[6]</sup>

XO-catalyzed oxidation of biological substrates (Hx and Xan), and inhibition of the enzyme by compounds with potential medical applications, have been described in the literature using the Michaelis–Menten equation. However, as outlined by Bardsley et al.,<sup>[7]</sup> experimental data obtained even for narrow ranges of substrate concentration showed pronounced deviation from the hyperbolic kinetics. Hence, interpretation of experimental data from XO-catalyzed processes in terms of classical parameters (K<sub>m</sub>, V<sub>max</sub> for substrates, and K<sub>i</sub> for inhibitors) is inappropriate.

Another important problem that has been overlooked in the studies of XO is the possible role of ionic forms of purine substrate in interactions with the enzyme and in catalysis. Xan has a  $pK_a$  of 7.7, which is attributed to ionization of N-3 position. Hence, in many physiological and pathological conditions there is a mixture of anionic and neutral forms of the substrate in solution.<sup>[8,9]</sup> This should be taken into account when analyzing kinetic data and constructing kinetic and molecular models of the XO catalytic mechanism.

### **EXPERIMENTAL**

Xanthine oxidase from bovine milk (EC 1.2.3.2) and xanthine were purchased from Sigma (St. Louis, MO). 2-chloroadenine (2ClAde) was synthesized according the procedure described previously.<sup>[10]</sup> Concentrations of the enzyme and substrates in solutions were determined from absorbance data using the respective molar extinction coefficients. For XO  $\varepsilon_{max}(280 \text{ nm}) = 202\ 600 \text{ M}^{-1}\text{cm}^{-1}$  was determined based on the amino acid sequence P80457 obtained from SwissProt database. For Xan  $\varepsilon_{max}(267 \text{ nm}) = 10,300 \text{ M}^{-1}\text{cm}^{-1}$  at pH 6.0,  $\varepsilon_{max}(270 \text{ nm}) = 9,100 \text{ M}^{-1}\text{cm}^{-1}$  at pH 7.5,  $\varepsilon_{max}(276 \text{ nm}) = 9,300 \text{ M}^{-1}\text{cm}^{-1}$  at pH 9.0; for 2ClAde  $\varepsilon_{max}(264 \text{ nm}) = 12,000 \text{ M}^{-1}\text{cm}^{-1}$  at pH 6.0,  $\varepsilon_{max}(264 \text{ nm}) = 11,900 \text{ M}^{-1}\text{cm}^{-1}$  at pH 7.5,  $\varepsilon_{max}(266 \text{ nm}) = 11,100 \text{ M}^{-1}\text{cm}^{-1}$  at pH 9.0. Due to low solubility, 2ClAde samples were first dissolved in a slightly alkaline medium (0.01 NaOH) and then diluted with a phosphate buffer of the appropriate pH value.

Enzymatic reactions have been performed at 25°C in 50 mM phosphate buffer in the pH range 5.8–9.0. Ultraviolet absorption spectra were recorded with an Uvikon 940 UV-VIS spectrophotometer (Kontron, Vienna, Austria), fitted with thermostatically controlled cell compartments. Oxidation of Xan was monitored at 300 nm corresponding to the uric acid absorption. Formation of 8-hydroxy-2chloroadenine, the oxidation product of 2ClAde, was monitored at 285 nm. Initial velocity of both processes was calculated using linear regression of absorbance *vs.* time.

Nonlinear regression analysis of the experimental data was performed using GraphPad Prism 3.0 (GraphPad Software Inc. ) and Origin 6.0 (Microcal) computer software packages. Rational functions of degree 2:2, 2:3 (Eqs. 1 and2), 3:2 and 3:3 were fitted<sup>[7]</sup> to kinetic data of initial velocity ( $v_o$ ) vs. initial substrate concentration ( $c_o$ ). Statistically significant decrease in the sum of residuals (as estimated with the Snedecor's F test at a 95% confidence level), residual plots, and P value from the runs test were used to identify major deviations from the equation selected, and to discriminate between various models.



**FIGURE 1** Kinetic of oxidation of Xan (left panels) and 2CldAde (right panels) catalyzed by XO. Reactions were conducted at  $25^{\circ}$ C in 50 mM phosphate buffer at pH values indicated. Fitting of the rational function of degree 2:2 (Eq. 1) and of degree 2:3 (Eq. 2) to the initial velocity data  $v_o(c_o)$  led to solid and broken lines, respectively.

#### **RESULTS AND DISCUSSION**

Our aim was to develop a suitable kinetic model for mammalian XO-mediated catalysis by studying the oxidation process of the natural substrate Xan and its structural analog 2ClAde over a wide range of the initial substrate concentrations (0.5–500  $\mu$ M) and in a broad range of pH values (5.8–9.0). The pK<sub>a</sub> = 7.7 of Xan deprotonation indicates that both in our experiments and in biological conditions there is a mixture of the neutral and monoanionic forms of Xan. The situation is quite different for 2ClAde. The pK<sub>a</sub> of 8.5 for this compound, which value was determined by spectrophotometrical titration, indicates that 2ClAde exists predominantly in the neutral form in the majority of biological environments.

The initial velocity data  $v_o(c_o)$  obtained for both compounds at pH 6.0, 7.5, 9.0 are presented in Figure 1. (Data obtained at pH 5.8, 6.5, 7.0, 8.0 and 8.5 are not shown). Kinetics at all pH values studied is clearly non-hyperbolic, hence the use of the Michaelis–Menten equation is not adequate. The data could be described as an apparent substrate inhibition, since maximal velocity is obtained for a relatively low initial substrate concentration (20–80  $\mu$ M, depending on pH and substrate employed), and the reaction rates are lower for higher  $c_o$ . The rates of oxidation are pH dependent. The maximum velocity is about 0.3, 0.6, and 0.6 U/mg for Xan, and 0.1, 0.2, and 0.2 U/mg for 2ClAde for pH 6.0, 7.5, and 9.0, respectively. Hence, pK<sub>a</sub> of the substrate appeared to not influence the pH dependence of the maximal rate of oxidation. However, substrate concentration corresponding to the maximal rate is pH dependent for Xan, and pH independent for 2ClAde (Figure 1), suggesting that the neutral form of Xan binds stronger to XO than the monoanion.

Nonlinear regression analysis of the kinetic data yielded adequate fits for rational functions of degree 2:2 for 2ClAde (Eq. 1) and 2:3 for Xan (Eq. 2, see Figure 1):

$$v_{o}(c_{o}) = \frac{jc_{o} + ic_{o}^{2}}{1 + mc_{o} + lc_{o}^{2}}$$
(1)

$$v_{o}(c_{o}) = \frac{jc_{o} + ic_{o}^{2}}{1 + mc_{o} + lc_{o}^{2} + kc_{o}^{3}}$$
(2)

These are the mathematical expressions describing several reaction mechanisms; constants i, j, k, l, and m represents combination of rate constants and their interpretation depends on the molecular mechanism.

Hence, in general, a rational function of degree at least 2:2 is necessary to describe kinetic data for XO. Such a function describes several possible molecular mechanisms of enzymatic reactions, e.g., allosteric interactions between enzyme subunits, steady-state random systems and many others (e.g., Refs. [7,11,12]). Steady-state kinetic data alone does not permit to distinguish unequivocally between various mechanisms. However, it is clear from the data presented here that

interpretation of kinetic data for XO on the basis of Michaelis–Menten model is incorrect. This should be given special consideration when describing new inhibitors of XO with potential medical applications. Determination of classical inhibition types and inhibition constants ( $K_i$ ) is not feasible for XO inhibition and may lead to incorrect conclusions regarding possible clinical application of candidate compounds. In this case,  $IC_{50}$  values seem to be more adequate to characterize inhibitory potency of new and previously synthesized analogues.

#### REFERENCES

- Hille, R.; Nishino, T. Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase. FASEB J. 1995, 9, 995–1003.
- Insel, P.A. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In *The Pharmacological Basis of Therapeutics*, 9th Ed.; Hardman, J.G., Gilman, A.G., Limbird, L.E., Eds.; McGraw-Hill: New York, 1995; 617–658.
- 3. Ellion, G.B. The purine path to chemotherapy. Science 1989, 244, 41-47.
- McCord, J.M. Oxygen-derived free radicals in post-ischemic tissue injury. N. Engl. J. Med. 1985, 312, 159– 163.
- Stevens, C.R.; Millar, T.M.; Clinch, J.G.; Kanczler, J.M.; Bodamyali, T.; Blake, D.R. Antibacterial properties of xanthine oxidase in human milk. Lancet 2000, 356, 829–830.
- Borges, F.; Fernandez, E.; Roleira, F. Progress towards the discovery of xanthine oxidase inhibitors. Curr. Med. Chem. 2002, 9, 195–217.
- Bardsley, W.G.; Leff, P.; Kavanagh, J.; Waight, R.D. Deviations from Michaelis-Menten kinetics. The possibility of complicated curves for simple kinetic schemes and the computer fitting of experimental data for acetylcholinesterase, acid phosphatase, adenosine deaminase, arylsulphatase, benzylamine oxidase, chymotrypsin, fumarase, galactose dehydrogenase, beta-galactosidase, lactate dehydrogenase, peroxidase and xanthine oxidase. Biochem. J. 1980, 187, 739-765.
- Kulikowska, E.; Kierdaszuk, B.; Shugar, D. Xanthine, xanthosine and its nucleotides: solution structures of neutral and ionic forms, and relevance to substrate properties in various enzyme systems and metabolic pathways. Acta Biochim. Pol. 2004, 57, 493–531.
- Cavalieri, L.; Fox, J.; Stone, A.; Chang, N. On the nature of xanthine and substituted xanthines in solution. J. Am. Chem Soc. 1954, 76, 1119–1122.
- Bzowska, A.; Magnowska, L.; Kazimierczuk, Z. Synthesis of 6-aryloxy-and 6-arylalkoxy-2-chloropurines and their interactions with purine nucleoside phosphorylase from *Escherichia coli*. Z. Naturforsch. 1999, 54c, 1055–1067.
- 11. Bardsley, W.G. Simple enzyme kinetic mechanisms that can give all possible velocity profiles with chemically reasonable rate constant values. J. Theor. Biol. **1983**, *104*, 485–491.
- 12. Segel, I.H. Enzyme Kinetics; John Wiley and Sons: New York, 1975.